What question did this study set out to answer?

This study aims to evaluate how the removal of the FDA’s in-person dispensing requirement affects access to mifepristone.

April 15, 2026

Changes in Mifepristone Use at Pharmacies After Removal of the FDA In-Person Dispensing Requirement

Key Points

This study aims to evaluate how the removal of the FDA’s in-person dispensing requirement affects access to mifepristone.
Cross-sectional design
Assessment of retail and mail-order pharmacy access
Comparison before and after the FDA policy change
Increased availability of mifepristone at retail pharmacies
Growth in mail-order pharmacy access
Greater overall access to medication after policy modification

Abstract

This cross-sectional study examines access to mifepristone through retail and mail-order pharmacies following the US Food and Drug Administration’s (FDA) removal of its in-person dispensing requirement.

Bookmark

Cite This Study

Scannell et al. (Mon,) studied this question.

synapsesocial.com/papers/69df2c2fe4eeef8a2a6b1437 https://doi.org/https://doi.org/10.1001/jama.2026.3419

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark